Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

New study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

Notably, 31.6% of patients receiving tirzepatide achieved at least 25% body weight loss (key secondary endpoint) compared with 16.1% of those taking semaglutide.

(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...

Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...

In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9 percent with early and late discontinuation and nondiscontinuation, respectively.

In SURMOUNT-1, people taking 15 mg of tirzepatide lost on average 22.5% of body weight -- representing a mean loss of 52 lb (24 kg) by week 72.